Thu Sep 12 00:05:59 UTC 2024: ## NKGen Biotech Reports Promising Early Results for Alzheimer’s Treatment
**SANTA ANA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE)** – NKGen Biotech, Inc. (NKGN), a clinical-stage biotechnology company focused on developing NK cell therapies, announced positive interim data from its Phase 1/2a clinical trial of troculeucel, its cryopreserved autologous enhanced NK cell therapy for moderate Alzheimer’s disease (AD).
Two out of the first three patients in the Phase 1 cohort, treated with the highest dose of 6 billion cells per treatment, showed significant improvement in their cognitive scores, resulting in a clinical upgrade from moderate AD to mild AD after only three months of treatment.
This promising data echoes similar results from the company’s MX04 Phase 1 AD study, where a moderate AD patient receiving the highest dose (4 billion cells) also saw a similar improvement.
“We are incredibly encouraged by these early findings,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “This data, coupled with the favorable safety profile observed in the Phase 1 cohort, strengthens our belief that troculeucel holds significant promise as a potential treatment for Alzheimer’s disease.”
The company has also initiated the Phase 2 cohort of the trial, enrolling the first patient. This randomized, double-blind, placebo-controlled trial will assess the efficacy of troculeucel against a placebo in a larger group of 30 moderate AD patients.
The trial aims to provide a comprehensive understanding of troculeucel’s potential benefits and limitations in treating Alzheimer’s disease, ultimately validating its potential therapeutic efficacy.
NKGen is expanding its clinical network, activating four sites across North America to further accelerate patient enrollment.
Six-month interim cognitive data from Phase 1 cohort patients receiving troculeucel is expected to be disclosed at an upcoming national Alzheimer’s conference in Q4 2024.
**About Troculeucel**
Troculeucel (formerly SNK01) is a novel cell-based, patient-specific ex vivo expanded autologous natural killer (NK) cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers.
The World Health Organization (WHO) has assigned troculeucel the International Nonproprietary Name (INN), which signifies a universally recognized nonproprietary drug name and marks a significant step towards bringing this therapy to market.
**About NKGen Biotech, Inc.**
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA.
First Piper 